ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Biosimilars

Biosimilars

@Planar/Shutterstock.com

Etanercept-szzs (Erelzi, Sandoz) has been approved by the U.S. Food and Drug Administration for RA and more.

©lenetstan/Shutterstock.com

A new report confirms that discounts for biosimilars do not determine global uptake and prescription incentives to encourage the use of biosimilars are hit and miss.

©Zonda/Shutterstock.com

Biosimilars to Humira and Enbrel are one step closer to the marketplace with FDA advisory committee approval.

Seth Ginsberg

Global Healthy Living Foundation and CreakyJoints president and co-founder, Seth Ginsberg, cautions against extrapolation, but is optimistic about biosimilars.

©ChaowalitSeeneha/Shutterstock.com

ARD study recommends against biosimilar switching for patients positive for anti-infliximab (Remicade) antibodies.

In this slideshow, we summarize the approved indications for the rheumatology biosimilar Inflectra (infliximab-dyyb), the boxed warnings and possible side effects.

©BillionPhotos/Shuttersstock.com

The U.S. approval of the first biosimilar in rheumatology, Inflectra, has been welcome news. Still, concerns about safety, interchangeability and costs dominate the discussions.

Pages

Subscribe to Biosimilars on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.